



ION CHANNELS DOWNUNDER

..... EDITED BY

DOMINIC GERAGHTY AND LACHLAN D. RASH

Series Editor S. J. Enna



ADVANCES IN
PHARMACOLOGY



VOLUME SEVENTY NINE

ADVANCES IN PHARMACOLOGY

Ion Channels DownUnder

Edited by

DOMINIC P. GERAGHTY

*School of Health Sciences, Faculty of Health,
University of Tasmania, Launceston, Australia*

LACHLAN D. RASH

*School of Biomedical Science, Faculty of Medicine,
University of Queensland, Brisbane, Australia*

Serial Editor


S.J. ENNA

*University of Kansas Medical Center, Kansas City,
Kansas, United States*

Managing Editor

LYNN LECOUNT

*University of Kansas Medical Center
School of Medicine, Kansas City, Kansas, United States*



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
525 B Street, Suite 1800, San Diego, CA 92101-4495, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
125 London Wall, London, EC2Y 5AS, United Kingdom

First edition 2017

Copyright © 2017 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-12-810413-2

ISSN: 1054-3589

For information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

Publisher: Zoe Kruze

Acquisition Editor: Zoe Kruze

Editorial Project Manager: Shellie Bryant

Production Project Manager: Vignesh Tamil

Cover Designer: Christian J. Bilbow

Typeset by SPi Global, India

CONTRIBUTORS

Murray J. Adams

School of Health Sciences, University of Tasmania, Launceston, TAS, Australia

John J. Bassett

School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia

Nicole A. Beard

John Curtin School of Medical Research, Australian National University, Canberra; Health Research Institute, Faculty of Education Science Technology and Mathematics, University of Canberra, Bruce, ACT, Australia

Philip G. Board

John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia

Amanda Buyan

Research School of Biology, Australian National University, Canberra, ACT, Australia

Marco G. Casarotto

John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia

Mary Chebib

Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia

Rong Chen

Research School of Biology, Australian National University, Canberra, ACT, Australia

Han Chow Chua

Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia

Ben Corry

Research School of Biology, Australian National University, Canberra, ACT, Australia

Jennifer R. Deuis

Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia

Angela F. Dulhunty

John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia

Argel Estrada-Mondragon

Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia

Dominic P. Geraghty

School of Health Sciences, University of Tasmania, Launceston, TAS, Australia

Mathilde R. Israel

Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia

Joseph W. Lynch

Queensland Brain Institute; School of Biomedical Sciences, University of Queensland, Brisbane, QLD, Australia

Mehdi Mobli

Centre for Advanced Imaging, St Lucia, QLD, Australia

Gregory R. Monteith

School of Pharmacy; Mater Research, The University of Queensland, Brisbane, QLD, Australia

Sofia A. Omari

School of Health Sciences, University of Tasmania, Launceston, TAS, Australia

Daniel P. Poole

Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology; The University of Melbourne, Parkville, VIC, Australia

Pradeep Rajas  khar

Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, VIC, Australia

Lachlan D. Rash

School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia

Sahil Talwar

Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia

Bryan Tay

Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia

Eivind A.B. Undheim

Centre for Advanced Imaging, St Lucia, QLD, Australia

Nicholas A. Veldhuis

Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology; The University of Melbourne, Parkville, VIC, Australia

Irina Vetter

Centre for Pain Research, Institute for Molecular Bioscience; School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia

Yan Zhang

Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia

PREFACE

Ion channels are the fastest cellular signaling system, underlying rapid processes such as axon conduction and synaptic transmission. However, ion channels are also found in nonexcitable cells and are indispensable for processes such as secretion, gene expression, and cell division. With over 140 members, ion channels are the second largest family of signaling molecules in the body and are activated by a diverse range of stimuli such as ligands, membrane voltage changes, temperature, stretch, and changes in pH. As “first responders,” a detailed understanding of ion channels is crucial to understanding how cells initially respond to changes in their environment.

There have been spectacular advances in this area in the past two decades, highlighted by the award of the 2003 Nobel Prize in Chemistry to Roderick MacKinnon for his determination of the 3D structure of a voltage-gated potassium channel. Despite the recent leaps and bounds of progress made in the area of ion channel structural biology (e.g., cryo-EM), it is our ability to selectively modulate ion channel function *in vitro* and *in vivo* that holds the key to unlocking the physiological and pathological roles of ion channels. To this end, high-quality ion channel pharmacology will provide the tools and therapeutic leads to address many unmet medical needs. The chapters in this volume demonstrate that the momentum has not changed and, indeed, has increased. Whether dissecting the activation of ryanodine receptors, describing the development of subunit-selective ligands for glycine and GABA receptors, or the contribution of calcium imaging in high-throughput identification of drug leads, the contributors have used state-of-the-art techniques and provided narratives and insights that will generate new ideas for years to come.

We wish to thank the many contributors to this volume. They have covered the pharmacology and role of a large number of channels in health and disease, and included some uniquely Australian research, such as employing peptides from our (many) venomous animals. You will no doubt

agree that *Ion Channels DownUnder* demonstrates the depth and breadth of excellent research being undertaken on the pharmacology ion channels around Australia.

DOMINIC P. GERAGHTY, PhD

School of Health Sciences, Faculty of Health,
University of Tasmania, Launceston, Australia

LACHLAN D. RASH, PhD

School of Biomedical Science, Faculty of Medicine,
University of Queensland, Brisbane, Australia

CONTENTS

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xi</i>
1. GABA_A Receptors and the Diversity in their Structure and Pharmacology	1
Han Chow Chua and Mary Chebib	
1. Introduction	2
2. Architecture of GABA _A Rs	3
3. GABA _A R Assembly: Selective Subunit Oligomerization	4
4. Multiple Subtypes, Locations, and Actions of GABA _A Rs	6
5. Subunit Stoichiometry and Arrangement of GABA _A Rs	9
6. Pharmacology of GABA _A Rs	12
7. Conclusion	24
Conflict of Interest	24
Acknowledgments	24
References	24
2. Acid-Sensing Ion Channel Pharmacology, Past, Present, and Future ...	35
Lachlan D. Rash	
1. Introduction	36
2. A Brief History of ASIC Pharmacology	42
3. The Current ASIC Tool Box	44
4. The Future: What Do We Need and Where Will It Come From	55
5. Conclusion	57
Conflict of Interest	58
Acknowledgments	59
References	59
3. Sodium Channels and Venom Peptide Pharmacology	67
Mathilde R. Israel, Bryan Tay, Jennifer R. Deuis, and Irina Vetter	
1. Introduction	68
2. Conclusion	102
Conflict of Interest	102
Acknowledgments	102
References	102

4. Role of Nonneuronal TRPV4 Signaling in Inflammatory Processes	117
Pradeep Rajasekhar, Daniel P. Poole, and Nicholas A. Veldhuis	
1. Introduction	118
2. Epithelial and Endothelial Cells	120
3. Glial Cells	125
4. Immune and Secretory Cells	129
5. Conclusion	132
Conflict of Interest	133
Acknowledgments	134
References	134
5. Genetically Encoded Calcium Indicators as Probes to Assess the Role of Calcium Channels in Disease and for High-Throughput Drug Discovery	141
John J. Bassett and Gregory R. Monteith	
1. Introduction	142
2. The Calcium Signal in Disease	145
3. The Calcium Signal as a Tool in Biomolecular Screening	146
4. Methods to Measure Cytosolic Calcium	148
5. New GECs	153
6. Targeting GECs	157
7. Application of GECs in the Assessment of Calcium Homeostasis in Disease	160
8. GECs and Biomolecular Screening	162
9. Conclusion	163
Conflict of Interest	163
Acknowledgments	163
References	163
6. TRPV1 Channels in Immune Cells and Hematological Malignancies	173
Sofia A. Omari, Murray J. Adams, and Dominic P. Geraghty	
1. Introduction	174
2. Overview of TRP Channels	175
3. TRPV1	176
4. TRPV1 Expression and Function in Immune Cells	179
5. TRPV1 in Hematological Malignancies	182
6. "Chili" and Vanilloids as Novel Chemotherapeutic Agents for Hematological Malignancies?	188
7. Conclusion	189
Conflict of Interest	189
References	190

7. Modulation of Ion Channels by Cysteine-Rich Peptides: From Sequence to Structure	199
Mehdi Mobli, Eivind A.B. Undheim, and Lachlan D. Rash	
1. Introduction	200
2. High-Throughput Production of DRPs	206
3. High-Throughput Toxin Structure Determination	209
4. Structure of Channel:Toxin Complexes	214
5. Conclusion	221
Conflict of Interest	221
Acknowledgments	221
References	221
8. Glycine Receptor Drug Discovery	225
Joseph W. Lynch, Yan Zhang, Sahil Talwar, and Argel Estrada-Mondragon	
1. Introduction	226
2. GlyR Subunits	228
3. GyRs and Disease	229
4. GlyR Pharmacology	236
5. Technologies for GlyR Drug Discovery	239
6. Progress Toward Developing GlyR-Targeted Analgesics	241
7. Conclusion	244
Conflict of Interest Statement	245
Acknowledgments	245
References	245
9. Voltage-Gated Sodium Channel Pharmacology: Insights From Molecular Dynamics Simulations	255
Rong Chen, Amanda Buyan, and Ben Corry	
1. Introduction	256
2. Molecular Dynamics Simulation Approaches	258
3. Sodium Channel–Toxin Interactions	261
4. Sodium Channel–Small Molecule Interactions	269
5. Conclusion	280
Acknowledgments	280
References	280
10. Physiology and Pharmacology of Ryanodine Receptor Calcium Release Channels	287
Angela F. Dulhunty, Philip G. Board, Nicole A. Beard, and Marco G. Casarotto	
1. Introduction	289
2. RyR Overview	289

3. Ion Channel Recording	292
4. EC Coupling	293
5. Pharmacology Arising From EC Coupling Studies	295
6. Regulation by Divalent Cations and CSQ	298
7. The FK506-Binding Proteins	302
8. CaM, Dantrolene, and S100A1	302
9. The Glutathione Transferase Structural Family	305
10. Oxidation, Phosphorylation, Doxorubicin, and Flecainide	307
11. Conclusion	310
Conflict of Interest	310
References	310



GABA_A Receptors and the Diversity in their Structure and Pharmacology

Han Chow Chua, Mary Chebib¹

Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia

¹Corresponding author: e-mail address: mary.collins@sydney.edu.au

Contents

1. Introduction	2
2. Architecture of GABA _A Rs	3
3. GABA _A R Assembly: Selective Subunit Oligomerization	4
4. Multiple Subtypes, Locations, and Actions of GABA _A Rs	6
5. Subunit Stoichiometry and Arrangement of GABA _A Rs	9
6. Pharmacology of GABA _A Rs	12
6.1 Orthosteric GABA Binding Sites	13
6.2 Benzodiazepine Binding Sites	16
6.3 Anesthetic Binding Sites in the TMD	18
6.4 Neurosteroid Binding Sites in the TMD	21
6.5 Variable Pharmacology of δ -Containing GABA _A Rs	22
6.6 Natural Products of Plant Origin	23
7. Conclusion	24
Conflict of Interest	24
Acknowledgments	24
References	24

Abstract

GABA_A receptors (GABA_ARs) are a class of ligand-gated ion channels with high physiological and therapeutic significance. In the brain, these pentameric receptors occur with diverse subunit composition, which confers highly complex pharmacology to this receptor class. An impressive range of clinically used therapeutics are known to bind to distinct sites found on GABA_ARs to modulate receptor function. Numerous experimental approaches have been used over the years to elucidate the binding sites of these drugs, but unequivocal identification is challenging due to subtype- and ligand-dependent pharmacology. Here, we review the current structural and pharmacological understanding of GABA_ARs, besides highlighting recent evidence which has revealed greater complexity than previously anticipated.

ABBREVIATIONS

CS read counter-clockwise when viewed from the extracellular side



1. INTRODUCTION

γ -Aminobutyric acid (GABA), the major inhibitory neurotransmitter in the mammalian central nervous system (CNS), is the conductor of an intricate inhibitory orchestra fundamental to the harmonious coordination of brain function. The inhibitory effects of GABA rely on two types of receptors—the fast-acting, Cl^- -conducting ionotropic GABA_A receptors ($\text{GABA}_\text{A}\text{Rs}$) and the slower-acting, G protein-coupled metabotropic GABA_B receptors ($\text{GABA}_\text{B}\text{Rs}$) (Note: GABA- and GABAR-mediated actions may be excitatory under certain circumstances, but these actions are not discussed in this chapter). $\text{GABA}_\text{A}\text{Rs}$ are ubiquitously expressed throughout the mammalian CNS and have indispensable physiological roles emphasized by a few lines of evidence. First, the mutation or deletion of various genes encoding for $\text{GABA}_\text{A}\text{R}$ subunits in mice is highly disruptive to the normal phenotype, causing developmental defects, sensorimotor dysfunction, hypersensitive behavior, anxiety, epilepsy, and/or reduced lifespan (DeLorey et al., 1998; Gunther et al., 1995; Homanics et al., 1997; Vien et al., 2015). Second, aberrant $\text{GABA}_\text{A}\text{R}$ trafficking, expression and/or gating effects have been implicated in autism (Fatemi, Reutiman, Folsom, & Thuras, 2009), schizophrenia (Mueller, Haroutunian, & Meador-Woodruff, 2014), and a range of idiopathic epileptic syndromes (Hirose, 2014) in humans. Furthermore, genetic association studies have also linked $\text{GABA}_\text{A}\text{R}$ subunit genes with alcohol dependence (Li et al., 2014), eating disorder outcomes (Bloss et al., 2011), autism (Collins et al., 2006; Ma et al., 2005), and bipolar disorders (Ament et al., 2015; Craddock et al., 2010).

$\text{GABA}_\text{A}\text{Rs}$ are also important drug targets, as evidenced by the successful clinical utilization of $\text{GABA}_\text{A}\text{R}$ modulators in the treatment of CNS-related disorders such as insomnia, anxiety, and epilepsy, as well as in the induction of anesthesia in surgical patients (Sieghart, 2015). While clinically useful, the misuse of these drugs poses risks of dependence, addiction, abuse, and life-threatening conditions associated with overdose or withdrawal. Hence, understanding the functions of $\text{GABA}_\text{A}\text{Rs}$ and the underlying mechanisms of the clinical and undesirable effects of $\text{GABA}_\text{A}\text{R}$ -targeting drugs to

improve the selectivity and safety of these therapeutics are topics of intensive research (Atack, 2010; Rudolph & Knoflach, 2011). However, the striking structural and functional heterogeneity of these channels pose major challenges in the study of GABA_ARs. In this chapter, we provide an overview of the structure and pharmacology of GABA_ARs. We also discuss recent evidence which highlights the potential for greater diversity in GABA_AR pharmacology due to subunit stoichiometric and arrangement differences.



2. ARCHITECTURE OF GABA_ARs

GABA_ARs are members of the pentameric ligand-gated ion channel (pLGIC) superfamily, which includes the nicotinic acetylcholine receptors (nAChRs), 5-hydroxytryptamine type 3 receptors (5-HT₃Rs), and glycine receptors. These receptors are made up of five homologous subunits that surround a central ion-conducting pore, a structure which is often likened to a barrel with five staves. Each receptor subunit has an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular domain (ICD). The ECDs are mostly made up of β -sheets and contribute to agonist binding sites, whereas the TMDs consist of the pore-forming α -helices and the structurally variable ICDs are involved in receptor assembly, trafficking and clustering.

The recent determination of a three-dimensional crystal structure of the $\beta 3$ homomeric GABA_AR captures structural details at 3 Å resolution (Miller & Aricescu, 2014). This receptor subtype is unlikely to be physiologically relevant, but its functional expression in heterologous systems is well known, and has been used as a model to study heteromeric GABA_ARs (Taylor et al., 1999; Yip et al., 2013). The receptor stands approximately 110 Å in height when viewed parallel to the membrane (Fig. 1A). The five subunits assemble in a doughnut-like shape with a diameter around 80 Å, when viewed from the extracellular space, down the channel pore (Fig. 1B). The large ECD (~65 Å in height) of each subunit is made up of an N-terminal α -helix followed by a β -sandwich core with 10 antiparallel β -sheets (Fig. 1C). The TMD consists of four membrane-spanning α -helices (M1–M4), with the M2 helices of all five subunits arranging themselves to form a tapered ion-conducting pore (Fig. 1B and C). The outermost M4 helix harbors the C-terminus on the extracellular end. The ICD contains a small M1–M2 loop and a much larger M3–M4 loop (G333–N446; residue numbering follows sequence of P28472 in UniProt) which was replaced with a 7-amino acid linker for the crystallization of this structure (Fig. 1C).




Fig. 1 The crystal structure of a human β_3 homomeric GABA_AR (PDB: 4COF). (A) Cartoon representation of GABA_AR viewed parallel to the membrane, colored according to secondary structures (α -helices are in *red* except for the pore-forming helices (*orange*), β -sheets are in *blue*). (B) *Left*, GABA_AR viewed from the extracellular space, with the five subunits labeled 1–5. *Right*, Transmembrane region of GABA_AR, with the ECDs simplified as *blue ovals* for clarity. The arrangement of the four TMDs (M1–M4), the C-terminus (*purple circles*), and the M2–M3 loop (*green*) are illustrated. (C) Topology of a single subunit of GABA_AR, *rainbow* colored from the N-terminus (*red*) to the C-terminus (*purple*). The β -sheets of the ECD, the α -helices of the TMDs, the characteristic Cys-loop, and other relevant loops are indicated. *Note*: the intracellular M3–M4 loop (G333–N446) was replaced with a 7-amino acid linker for crystallization. Figures were prepared using Maestro, v. 9.5.014, Schrödinger, LLC.

3. GABA_AR ASSEMBLY: SELECTIVE SUBUNIT OLIGOMERIZATION

Human genome sequencing has identified at least 19 GABA_AR subunit genes (α 1–6, β 1–3, γ 1–3, δ , ϵ , θ , π , and ρ 1–3). Given the heteromeric nature of GABA_ARs *in vivo*, this long list of subunits, together with the

splice variants of some of the subunits allow for an enormous range of theoretically possible subunit combinations. Yet, experimental evidence suggests that only a few dozen combinations exist *in vivo* (see Section 4), indicating that GABA_AR assembly is a selective, and not a random process. A hierarchical assembly mechanism has been proposed, in which certain subunits are preferred over others to form dimeric intermediates that ultimately assemble into pentameric complexes (Sarto-Jackson & Sieghart, 2008).

Different methods have been used to define the rules underlying receptor assembly. In concert, data obtained using functional, immunoimaging, and sucrose gradient centrifugation techniques suggest that both α and β subunits are obligatory for the surface expression of fully functional pentameric receptors in heterologous cell systems (Angelotti, Uhler, & Macdonald, 1993; Connor, Boileau, & Czajkowski, 1998; Gorrie et al., 1997). The additional third γ subunit has been shown to enhance the efficiency of receptor assembly (Tretter, Ehya, Fuchs, & Sieghart, 1997). In contrast, the recombinant expression of individual α , β , and γ subunits, and the $\alpha\gamma$ and $\beta\gamma$ combinations mainly yielded di-, tri-, and tetrameric oligomers which were retained in the endoplasmic reticulum (Connolly, Krishek, McDonald, Smart, & Moss, 1996; Gorrie et al., 1997). There are a few notable exceptions, however, with the homomeric $\beta 1$ and $\beta 3$ and the heteromeric $\beta 3\gamma 2$ receptors expressing readily in heterologous systems (Chua, Absalom, Hanrahan, Viswas, & Chebib, 2015; Sanna et al., 1999; Taylor et al., 1999; Woollorton, Moss, & Smart, 1997).

Amino acid residues important for assembly have been identified in several studies using the chimeric receptor and site-directed mutagenesis approaches (Sarto-Jackson & Sieghart, 2008). These residues are found mainly in the ECD, and to a lesser extent in the intracellular M3–M4 loop. In accordance with these data, the $\beta 3$ GABA_AR crystal structure revealed extensive energetically favorable interactions such as hydrogen bonds, salt bridges, and van der Waals forces along the interfaces between subunit ECDs (Miller & Aricescu, 2014). Disruption to these interactions could affect receptor assembly, and may be the reason for impaired GABA_AR surface expression with epilepsy-associated mutations found in the N-terminal regions such as $\beta 3G32R$ and $\gamma 2R43Q$ (Frugier et al., 2007; Gurba, Hernandez, Hu, & Macdonald, 2012; Sancar & Czajkowski, 2004).

While considerable insights have been provided by these studies, the molecular determinants could not be firmly established for several reasons. First, these determinants differ depending on the partner subunits.

For example, four residues in the ECD of the $\beta 3$ subunit (G171, K173, E179, and R180) have been identified to be critical for the assembly of $\beta 3$ and $\beta 3\gamma 2$ receptors, but they are not compulsory for the assembly of $\alpha\beta$ receptors (Taylor et al., 1999). In another study that investigated the role of the N-terminal regions in the expression of $\alpha 1\beta 2\gamma 2$ GABA_ARs, subunit-specific contributions to receptor assembly were found (Wong, Tae, & Cromer, 2015). When deleted, the N-terminus of the $\alpha 1$ subunit had the most prominent effect on the expression of $\alpha 1\beta 2\gamma 2$ receptors, whereas deletion in similar regions of the $\beta 2$ and $\gamma 2$ subunits had minimal effect on surface expression. Second, multiple residues may be involved in oligomerization with the same neighboring subunit (Sarto et al., 2002). As such, when a putative binding residue is mutated and has no effect on receptor expression, it does not necessarily indicate no participation in intersubunit linking. Conversely, an expression-impairing mutation does not validate its significance in subunit oligomerization, as the residue may indirectly contribute to this process (e.g., by stabilizing interacting regions). All in all, GABA_AR assembly is a highly complex, multistep process which involves subunit-specific determinants that govern the subunit composition of GABA_ARs found natively.



4. MULTIPLE SUBTYPES, LOCATIONS, AND ACTIONS OF GABA_ARs

In recent years, it has become evident that the multiplicity in GABA_AR subunit composition (or subtypes) is one of the main reasons for the heterogeneity observed in their cellular and subcellular distributions, biophysical characteristics, pharmacological properties, in addition to physiological functions (Farrant & Nusser, 2005; Jacob, Moss, & Jurd, 2008; Rudolph, Crestani, & Möhler, 2001). Furthermore, the subunit composition of GABA_ARs is plastic. Alterations in brain GABA_AR subtypes have been reported under various developmental and pathological conditions (Brooks-Kayal, Shumate, Jin, Rikhter, & Coulter, 1998; Fritschy, Paysan, Enna, & Mohler, 1994; Steiger & Russek, 2004). As such, answering the question “which GABA_AR subtypes actually occur in vivo?” is essential to understanding the diverse roles played by GABAergic inhibition.

Currently, existing experimental techniques are unable to unequivocally identify GABA_AR subunit composition in neurons. To help determine the likelihood of a receptor subtype being expressed physiologically, the IUPHAR committee has introduced five classification criteria (Olsen &